PSC occurs in 1 out of 10,000 people, who are mostly male adults between 30 and 60 years old, and it commonly develops in ...

Wuhan YZY Biopharma Co., Ltd. Class H ( ($HK:2496) ) has issued an update. Wuhan YZY Biopharma has received Investigational New Drug approval from ...

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...

Multiple myeloma (MM) is the second most common hematologic malignancy, characterized by the uncontrolled growth of plasma cells and progressive ...

Discover how artificial intelligence is transforming influenza vaccine development, accelerating timelines and improving ...

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...

Scientists present a new approach that could empower the immune system to combat cancer cells and pave the way for new treatments for this deadly ...

Multiple myeloma is an incurable plasma cell malignancy despite major therapeutic advances. A recent review by Chinese ...

Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027BRIDGEWATER, ...

The Maryland life sciences campus is part of a package deal alongside Human Genome Sciences, which Samsung is acquiring from ...

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz ® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based ...

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply networkAdditional ...